Eupraxia Pharmaceuticals Reports Six-Month Symptom Data From The Highest Dose Cohort In Its Ongoing Phase 1B/2A RESOLVE Trial In Eosinophilic Esophagitis March 17, 2026 mental-health ONLY AVAILABLE IN PAID PLANS. Originally reported by menafn. Read more Source: https://menafn.com/1110871803/Eupraxia-Pharmaceuticals-Reports-Six-Month-Symptom-Data-From-The-Highest-Dose-Cohort-In-Its-Ongoing-Phase-1B2A-RESOLVE-Trial-In-Eosinophilic-Esophagitis
